PSMA PET/CT for GBM patients on bevacizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, single-arm study enrolls adults with IDH-wildtype glioblastoma who are already receiving bevacizumab. Participants undergo PSMA PET/CT imaging to explore the relationship between PSMA expression and VEGF blockade in glioblastoma. The goal is to understand tumor biology and imaging markers that may inform future therapeutic strategies. The study is conducted at Royal North Shore Hospital in Australia and does not introduce a new active treatment beyond standard bevacizumab plus imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \> 18 year of age
* ECOG 0-2
* Able to provide informed consent for the study
* Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
* Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
* For bevacizumab treatment as per treating physician
* Able to comply with trial requirements

Exclusion Criteria:

* No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
* Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
* Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
* Does not fulfill PBS requirements for bevacizumab
* Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Where it's running

• Royal North Shore Hospital
  Saint Leonards, New South Wales, Australia Recruiting

Study contacts

• Study coordinator: Alexander Yuile
• Email: Alexander.Yuile@health.nsw.gov.au
• Phone: +61 2 94631171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Trimipramine with atezolizumab and bevacizumab for recurrent glioblastoma

  Researchers will try whether adding the antidepressant trimipramine to the immunotherapy atezolizumab plus bevacizumab helps people with recurrent glioblastoma.

  Recruiting at 7 sites Phase 2 Centre Hospitalier Universitaire Vaudois · Basel, Basel and 6 other locations · NCT07263438

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Monitoring soluble CD146 levels in glioblastoma patients treated with bevacizumab

  This study is testing if tracking a specific protein in the blood can help understand how well glioblastoma patients are responding to treatment with bevacizumab.

  Recruiting Assistance Publique Hopitaux De Marseille · Marseille · NCT06001281

• Infusion of Bevacizumab with Chemotherapy and Radiation for Newly Diagnosed Glioblastoma

  This study is testing if adding a special infusion of Bevacizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma live longer and feel better.

  Recruiting Phase 3 Northwell Health · New York, New York · NCT05271240

• Combining capecitabine and temozolomide for newly diagnosed glioblastoma

  This study is testing if combining two cancer drugs, capecitabine and temozolomide, can help people with newly diagnosed glioblastoma live longer and feel better compared to using temozolomide alone.

  Recruiting Phase 1/2 Northwell Health · New York, New York · NCT03213002

• Biomarkers to predict 6‑month survival with Avastin in first‑relapse glioblastoma

  This project will test whether early MRI spectroscopy markers can predict which people with first‑relapse glioblastoma treated with Avastin will live six months or longer.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT03144167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.